Henrik Busch-Larsen

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Part of Phytera, Inc., Auda Pharmaceuticals ApS provides proprietary combinatorial chemistry technologies. Auda Pharmaceuticals was acquired by Phytera, Inc. from Danish Development Finance Corp on March 17, 1997.

Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million.

PNA-Diagnostics A/S manufactures medical diagnostic equipment. The firm is a subsidiary of Applera Corp. The company is headquartered in Copenhagen, Denmark

Vivostat A/S provides cardiac, thoracic and orthopaedic surgery medical devices. It offers vivostat system, an automated system for the on-site preparation and application of patient-derived fibrin sealant or platelet rich fibrin. Its products include Vivostat autologous fibrin sealant for various settings in surgical areas, transfusion centers, or blood banks and Vivostat platelet rich fibrin, which utilizes the patient's own blood to derive either a surgical sealant to prevent and stop bleedings, or a gel with a high concentration of growth factors that stimulates the healing of chronic wounds, as well as provides application devices. The compnay was founded in 2001 by Tom Bjerg Lauritzen and Niels Hvid and is headquartered in Alleroed, Denmark.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors.

ORIGIO A/S manufactures and markets assisted reproduction technologies and related human reproductive products. Its products include Andrology, sequential series, EmbryoGem, BlastGen, Pipettes, ICSI micropipets. The company was founded in 1987 and is headquartered in Maaloev, Denmark.

Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark.

Puris Proteins LLC produces plant-based, non-GMO sustainable food ingredients. The firm?s products include pea starch, whole pea hull fiber, pea syrup, whole pulse powders, whole grains and ready to eat pea fiber. The company is headquartered in Minneapolis, MN.

Maersk Growth (Maersk Growth) is the venture capital arm of the listed company A.P. Møller-Mærsk A/S (CPH:MAERSK). The firm was founded in 2017 and is headquartered in Copenhagen, Denmark.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Clean Power Hydrogen Group Ltd. develops hydrogen production and storage equipment. The company was founded on July 19, 2016 and is headquartered in London, the United Kingdom.

Double Bioventures Ltd. is a British company founded in 2018 that builds non-traditional life-science companies in non-traditional ways. The private company is based in London, UK. The company focuses on identifying opportunities outside core therapeutics and developing robust business models for such businesses. The company aims to help life-science ventures play a wider role in meeting the challenges of the modern world.

Sundew ApS targets water-borne pests and diseases. The company is based in Copenhagen, Denmark. and has subsidiaries in Ireland. The Danish company was founded in 2018 by Neil Goldsmith, Jørgen Hansen, Andy Gardiner. Giovanni Salerno has been the CEO of the company since 2021.

Chosa ApS is a Danish company that provides biotechnology services. The private company is based in Copenhagen, Denmark. The CEOs are Claus Frisenberg Pedersen and Neil Goldsmith. The company was founded in 2022.